Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8404MR)

This product GTTS-WQ8404MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Diffuse Large B Cell Lymphoma (DLBCL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8404MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4844MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BT-062
GTTS-WQ1675MR IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACZ885
GTTS-WQ7029MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Fab C225
GTTS-WQ11909MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MLN-1202
GTTS-WQ14681MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SCT-400
GTTS-WQ3960MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ112MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 11F8
GTTS-WQ15187MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA TA-650
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW